(Reuters) -Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.
The trial was testing a 7.2 milligram dose of the drug, compared with a 2.4 milligram dose and a placebo, all administered once weekly.
In the trial, which included 1,407 participants with obesity, the drug was statistically significant and superior to the placebo in reducing weight, the drugmaker said.
Those on the higher dose achieved weight loss of 20.7% after 72 weeks, compared 17.5% for the 2.4 milligram dose and 2.4% for the placebo.
Novo Nordisk added that 33.2% of the participants who received the higher dose achieved a weight loss of 25% or more after 72 weeks, compared with 16.7% for the 2.4 milligram dose.
Detailed results from the trial are expected to be presented at a scientific conference in 2025, according to the company.
Results from a second late-stage trial testing a 7.2 milligram dose of the drug in adults with type 2 diabetes and obesity are expected within the next few months.
(Reporting by Stine Jacobsen in Copenhagen and Sriparna Roy in Bengaluru; Editing by Terje Solsvik and Shounak Dasgupta)
Comments